In a new study, Lupkynis™ (voclosporin) for lupus nephritis (LN) treatment proved effective for controlling LN regardless of the disease classification. Delays in LN diagnosis and incomplete responses to treatment can potentially increase kidney damage and other disease complications in people with lupus. Lupkynis treatment can improve kidney response regardless of disease progression at diagnosis.

Researchers reviewed pooled data from two studies of 532 people with complete renal response by LN biopsy class. Lupkynis, in combination with mycophenolate mofetil (MMF) and low-dose corticosteroids, led to treatment benefits across biopsy class subgroups compared with treatment with MMF and low-dose corticosteroids alone (placebo).

Lupkynis was approved by the Food and Drug Administration for LN treatment earlier this year. Consult your physician before making changes to your medication and continue to follow the Lupus Foundation of America for updates on voclosporin. Learn more about treatments being studied for lupus.

Read the study